A small reset in fair value to €143.20, together with individual analyst targets moving to €135 from €150 and to €130 from €125, has put fresh focus on how Merck KGaA is being framed right now. These ...

Merck KGaA (ETR:MRK) executives told investors the company delivered “solid” organic growth in 2025 despite a challenging ...

Add Yahoo as a preferred source to see more of our stories on Google. Merck KGaA will progress its ADC Merck KGaA's antibody-drug conjugate (ADC), precemtabart tocentecan (Precem-TcT), has shown ...

Merck KGaA (MKGAF) stock drops as the company projects a disappointing revenue and adjusted EBITDA outlook for 2026. Read more here.

The company anticipates currency headwinds would continue to weigh on its earnings this year, as the life-sciences and ...

By Ludwig Burger and Patricia Weiss FRANKFURT, March 5 (Reuters) - Germany's Merck KGaA projected 2026 adjusted operating profit to slip by as much as 9.8%, hurt by negative currency effects and the ...

Merck KGaA expects its 2026 adjusted operating profit to decrease by up to 4%, excluding currency effects, according to its latest statement.

Q4 2025 Press Conference Call March 5, 2026 4:00 AM ESTCompany ParticipantsAxel Lober - Head of Global CommunicationsBelén Garijo López ...

Investing.com -- Merck KGaA (ETR:MRCG) on Thursday warned adjusted operating profit margins would shrink in 2026 as patent losses on its top-selling multiple sclerosis drug and currency headwinds ...

Sanofi has replaced its CEO Paul Hudson after a series of R&D setbacks at the French pharma, handing the reins to Merck KGaA leader Belén Garijo, M.D., Ph.D. Following the departure of GSK CEO Emma ...

DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany (DAX: MRK), a leading science and technology company, and SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a Stamford, ...